Hospital
Kadlec Regional Medical Center
Kadlec Regional Medical Center was paid $151.60M by Medicaid between Jan 2018 and Dec 2024, across 703 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 21% of everything it billed.
33Billing provider infoKADLEC REGIONAL MEDICAL CENTER
RICHLAND, WA 99352
RICHLAND, WA 99352
33aNPI1972507580assigned 06/10/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$151.60M
24GClaims3,639,406
24DCodes billed703
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Washington
Rank by total paid#1 of 49
Median peer was paid$20.06M
This provider vs. median7.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 639,733 | $26.64M | |
| 2019 | 580,197 | $24.15M | |
| 2020 | 464,038 | $18.26M | |
| 2021 | 523,547 | $20.52M | |
| 2022 | 517,790 | $22.78M | |
| 2023 | 499,227 | $20.78M | |
| 2024incomplete | 414,874 | $18.47M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 21% | 377,050 | 310,562 | $31.71M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.2% | 117,675 | 110,898 | $13.96M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.8% | 240,161 | 228,502 | $11.78M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.4% | 193,321 | 185,262 | $8.20M |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.3% | 26,319 | 23,111 | $7.99M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.2% | 69,187 | 64,105 | $6.40M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.4% | 41,662 | 38,621 | $3.59M |
| J9271 | Injection, pembrolizumab, 1 mg | 1.9% | 695 | 526 | $2.84M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.5% | 13,239 | 12,800 | $2.29M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 21,020 | 20,189 | $1.88M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.1% | 39,284 | 16,641 | $1.72M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.1% | 20,558 | 20,454 | $1.64M |
691 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 16,489 | $1.62M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.0% | 56,140 | $1.57M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 38,363 | $1.45M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 15,148 | $1.45M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 10,488 | $1.41M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 17,786 | $1.35M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 17,365 | $1.27M |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 9,138 | $1.24M |
| 44970 | <1% | 381 | $1.17M | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 29,160 | $1.13M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 7,996 | $1.07M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 4,420 | $1.05M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 5,408 | $947K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 10,524 | $918K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 31,326 | $882K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 7,816 | $865K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 12,228 | $859K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 4,549 | $794K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 9,232 | $769K |
| 99479 | Subsequent intensive care, per day, very low birth weight infant | <1% | 9,948 | $737K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 2,254 | $710K |
| 96415 | <1% | 3,763 | $704K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 10,112 | $704K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 3,074 | $681K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 11,279 | $627K |
| 76830 | Ultrasound, transvaginal | <1% | 8,920 | $598K |
| 99223 | Prolong inpt eval add15 m | <1% | 7,883 | $575K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,612 | $555K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 9,756 | $547K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 2,870 | $537K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 7,650 | $533K |
| 17110 | <1% | 3,067 | $529K | |
| 12001 | <1% | 2,573 | $521K | |
| 99480 | Subsequent intensive care, per day, low birth weight infant | <1% | 5,853 | $425K |
| 80053 | Comprehensive metabolic panel | <1% | 92,593 | $422K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 19,802 | $421K |
| 96367 | <1% | 6,485 | $415K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,263 | $409K |
| 62323 | <1% | 2,965 | $403K | |
| 64615 | <1% | 2,460 | $401K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 14,183 | $392K |
| 90960 | End-stage renal disease related services monthly, for patients 20 years and older, with 4 or more face-to-face visits | <1% | 6,152 | $380K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 5,063 | $376K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 11,746 | $362K |
| 12011 | <1% | 1,620 | $356K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,928 | $356K |
| 97113 | <1% | 7,227 | $353K | |
| 76775 | <1% | 4,347 | $352K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 6,827 | $347K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 807 | $345K |
| G0378 | Hospital observation service, per hour | <1% | 18,394 | $333K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,817 | $332K |
| 59025 | Fetal non-stress test | <1% | 4,620 | $332K |
| 76642 | <1% | 4,141 | $323K | |
| J2323 | Injection, natalizumab, 1 mg | <1% | 311 | $322K |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | <1% | 549 | $319K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 11,979 | $315K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 6,442 | $311K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 6,534 | $307K |
| 93971 | <1% | 3,794 | $302K | |
| 97161 | <1% | 6,865 | $301K | |
| 99469 | Subsequent inpatient neonatal critical care, per day, 28 days or younger | <1% | 1,259 | $299K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 4,428 | $279K |
| 92523 | <1% | 2,236 | $278K | |
| 90686 | <1% | 19,639 | $275K | |
| 92588 | <1% | 2,307 | $272K | |
| 52000 | <1% | 503 | $267K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 6,526 | $266K |
| 96416 | <1% | 1,150 | $265K | |
| 31575 | <1% | 1,869 | $264K | |
| 99460 | <1% | 3,508 | $254K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,716 | $245K |
| 76536 | <1% | 2,792 | $237K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 4,390 | $235K |
| 92557 | <1% | 5,663 | $225K | |
| 36902 | <1% | 200 | $217K | |
| 76801 | <1% | 4,698 | $217K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 4,107 | $208K |
| 93017 | <1% | 2,415 | $197K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 6,142 | $193K |
| 95819 | <1% | 964 | $193K | |
| 87631 | <1% | 4,148 | $188K | |
| 70498 | <1% | 1,615 | $181K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 12,898 | $180K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 1,878 | $178K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,946 | $176K |
| 29105 | <1% | 864 | $173K | |
| 90670 | <1% | 11,987 | $164K | |
| 72141 | <1% | 1,376 | $162K | |
| 10060 | <1% | 766 | $159K | |
| 47563 | <1% | 77 | $159K | |
| 92526 | <1% | 3,277 | $158K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 6,467 | $157K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 27,943 | $156K |
| 93970 | <1% | 1,789 | $148K | |
| 29125 | <1% | 836 | $147K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,243 | $146K |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | <1% | 937 | $146K |
| 76870 | <1% | 1,618 | $144K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 4,385 | $144K |
| 70496 | <1% | 1,667 | $142K | |
| 70491 | <1% | 1,198 | $139K | |
| 74183 | <1% | 643 | $137K | |
| 92567 | <1% | 10,577 | $136K | |
| 11045 | <1% | 510 | $135K | |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | <1% | 289 | $134K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 648 | $133K |
| 12002 | <1% | 659 | $130K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 1,519 | $123K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,338 | $121K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 1,106 | $118K |
| 84484 | <1% | 27,684 | $112K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 13,403 | $107K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 10,251 | $106K |
| 95886 | <1% | 1,705 | $106K | |
| 99205 | Prolong outpt/office vis | <1% | 946 | $105K |
| 71250 | <1% | 2,209 | $105K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 1,708 | $102K |
| 90680 | <1% | 7,259 | $100K | |
| 94726 | <1% | 3,181 | $99K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 857 | $98K |
| 90961 | <1% | 1,340 | $95K | |
| 94060 | <1% | 3,941 | $95K | |
| 97162 | <1% | 2,356 | $95K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 5,943 | $92K |
| 11102 | <1% | 598 | $92K | |
| 20553 | <1% | 969 | $92K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 304 | $90K |
| 97165 | <1% | 1,950 | $87K | |
| 70486 | <1% | 1,661 | $85K | |
| 90698 | <1% | 5,848 | $84K | |
| 36430 | <1% | 895 | $83K | |
| 20610 | <1% | 1,029 | $80K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 72 | $80K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 1,517 | $78K |
| 76882 | <1% | 1,067 | $78K | |
| 92579 | <1% | 1,744 | $77K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 5,064 | $74K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 8,299 | $72K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 701 | $72K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 7,260 | $71K |
| 95816 | <1% | 429 | $71K | |
| 90633 | <1% | 4,822 | $66K | |
| 99243 | <1% | 942 | $65K | |
| 87040 | <1% | 8,500 | $65K | |
| 76937 | <1% | 2,329 | $65K | |
| 77066 | Tomosynthesis, mammo | <1% | 2,585 | $65K |
| 77014 | <1% | 2,014 | $64K | |
| 73630 | <1% | 10,238 | $63K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,468 | $63K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 46,316 | $63K |
| 74018 | <1% | 5,458 | $62K | |
| 97802 | <1% | 1,170 | $62K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 14,775 | $61K |
| 94729 | <1% | 3,390 | $60K | |
| J3490 | Unclassified drugs | <1% | 3,731 | $60K |
| 47562 | <1% | 44 | $60K | |
| 76825 | <1% | 393 | $59K | |
| 97803 | <1% | 1,692 | $57K | |
| 10061 | <1% | 287 | $57K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 28,332 | $55K |
| 69210 | <1% | 2,414 | $54K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 163 | $54K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 768 | $53K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,265 | $51K |
| 76821 | <1% | 1,003 | $50K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,592 | $50K |
| 92508 | Group treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,769 | $50K |
| 58300 | <1% | 156 | $50K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,897 | $49K |
| 31231 | <1% | 330 | $49K | |
| 90715 | <1% | 2,816 | $49K | |
| 11100 | <1% | 240 | $47K | |
| 83605 | <1% | 9,362 | $46K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 1,208 | $46K |
| 72100 | <1% | 4,529 | $45K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,835 | $45K |
| 76820 | <1% | 1,790 | $44K | |
| 36561 | <1% | 40 | $43K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 47,177 | $42K |
| 82553 | <1% | 6,004 | $42K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 103,589 | $41K |
| 93975 | <1% | 552 | $40K | |
| 58662 | <1% | 14 | $40K | |
| 29515 | <1% | 213 | $40K | |
| 92585 | <1% | 165 | $40K | |
| 95911 | <1% | 364 | $39K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 157 | $39K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 12,300 | $38K |
| 99381 | <1% | 558 | $38K | |
| 73030 | <1% | 4,843 | $38K | |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 47 | $37K |
| 90744 | <1% | 2,457 | $37K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 40,071 | $36K |
| 93880 | <1% | 965 | $36K | |
| 76813 | <1% | 548 | $35K | |
| 73562 | <1% | 4,975 | $35K | |
| 72110 | <1% | 1,597 | $35K | |
| 97116 | <1% | 2,246 | $34K | |
| 73610 | <1% | 6,691 | $33K | |
| 85379 | <1% | 6,479 | $33K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 36,983 | $33K |
| 11750 | <1% | 122 | $33K | |
| 71045 | Radiologic examination, chest; single view | <1% | 22,465 | $33K |
| 73110 | <1% | 4,395 | $32K | |
| 74230 | <1% | 391 | $32K | |
| 92610 | <1% | 823 | $31K | |
| 96040 | <1% | 765 | $30K | |
| 77427 | <1% | 457 | $29K | |
| 74174 | <1% | 148 | $29K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 750 | $27K |
| 99462 | <1% | 801 | $27K | |
| 97129 | <1% | 141 | $26K | |
| 72040 | <1% | 2,324 | $26K | |
| 97166 | <1% | 500 | $25K | |
| 73130 | <1% | 4,102 | $24K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 879 | $24K |
| 90677 | <1% | 1,566 | $24K | |
| 90723 | <1% | 2,135 | $23K | |
| 93922 | <1% | 706 | $23K | |
| 59400 | Routine obstetric care including antepartum care, vaginal delivery, and postpartum care | <1% | 13 | $23K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 976 | $23K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 180 | $23K |
| 90648 | <1% | 1,807 | $22K | |
| 96127 | <1% | 9,255 | $22K | |
| 73221 | <1% | 222 | $22K | |
| 83880 | <1% | 5,298 | $22K | |
| 17000 | <1% | 172 | $22K | |
| 84145 | <1% | 2,446 | $21K | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 3,665 | $21K |
| 93320 | <1% | 767 | $21K | |
| 92587 | <1% | 130 | $21K | |
| 87632 | <1% | 438 | $20K | |
| 90966 | <1% | 260 | $20K | |
| 11900 | <1% | 83 | $19K | |
| 87641 | <1% | 2,160 | $19K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 3,000 | $19K |
| 93798 | <1% | 3,215 | $18K | |
| 99254 | <1% | 171 | $17K | |
| 76827 | <1% | 420 | $17K | |
| 20550 | <1% | 156 | $16K | |
| 88307 | <1% | 923 | $16K | |
| 73502 | <1% | 2,173 | $16K | |
| 95909 | <1% | 247 | $15K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 986 | $15K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 1,209 | $14K |
| 72131 | <1% | 272 | $14K | |
| 19083 | <1% | 27 | $14K | |
| 77336 | <1% | 492 | $14K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 18 | $14K |
| 99152 | <1% | 7,388 | $14K | |
| 80050 | General health panel | <1% | 2,680 | $14K |
| 81001 | <1% | 56,693 | $14K | |
| 58558 | <1% | 13 | $13K | |
| 72197 | <1% | 76 | $13K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,450 | $13K |
| 90647 | <1% | 1,258 | $13K | |
| 74178 | <1% | 89 | $13K | |
| 87420 | <1% | 1,445 | $12K | |
| 71271 | <1% | 170 | $12K | |
| 90716 | <1% | 1,064 | $12K | |
| 72158 | <1% | 107 | $12K | |
| 99220 | <1% | 187 | $12K | |
| 72146 | <1% | 57 | $12K | |
| 93296 | <1% | 1,411 | $12K | |
| 81025 | <1% | 15,743 | $12K | |
| 90707 | <1% | 996 | $12K | |
| 84112 | <1% | 1,570 | $12K | |
| 87486 | <1% | 1,080 | $11K | |
| 90962 | <1% | 266 | $11K | |
| 83735 | <1% | 14,832 | $11K | |
| 93000 | <1% | 1,311 | $11K | |
| 72072 | <1% | 1,145 | $11K | |
| 59820 | <1% | 12 | $11K | |
| 99383 | <1% | 126 | $11K | |
| 82247 | <1% | 1,929 | $11K | |
| 77080 | <1% | 233 | $11K | |
| 92551 | <1% | 1,395 | $11K | |
| 90651 | <1% | 763 | $10K | |
| 73140 | <1% | 2,726 | $10K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 1,309 | $10K |
| 76770 | <1% | 125 | $10K | |
| 64493 | <1% | 46 | $10K | |
| 73560 | <1% | 997 | $10K | |
| 86850 | <1% | 6,926 | $9K | |
| 96111 | <1% | 52 | $9K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,142 | $9K |
| 92611 | <1% | 365 | $9K | |
| 90697 | <1% | 475 | $9K | |
| 76857 | <1% | 203 | $9K | |
| 87581 | <1% | 1,080 | $9K | |
| 93976 | <1% | 257 | $9K | |
| 29075 | <1% | 174 | $9K | |
| 0071A | <1% | 233 | $8K | |
| 99443 | <1% | 179 | $8K | |
| 85027 | <1% | 6,979 | $8K | |
| 73080 | <1% | 1,809 | $8K | |
| 64483 | <1% | 24 | $8K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,538 | $8K |
| 58301 | <1% | 72 | $8K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 65 | $7K |
| 93325 | <1% | 1,308 | $7K | |
| 72050 | <1% | 394 | $7K | |
| 73590 | <1% | 1,850 | $7K | |
| 93270 | <1% | 203 | $7K | |
| 90710 | <1% | 509 | $7K | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 387 | $7K |
| 92550 | <1% | 71 | $7K | |
| 0072A | <1% | 184 | $7K | |
| 86900 | <1% | 9,333 | $7K | |
| 96376 | <1% | 10,050 | $6K | |
| 93926 | <1% | 218 | $6K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 570 | $6K |
| 99242 | <1% | 112 | $6K | |
| 93016 | <1% | 610 | $6K | |
| 92522 | <1% | 97 | $6K | |
| 86140 | <1% | 15,512 | $6K | |
| 62321 | <1% | 58 | $5K | |
| 84703 | <1% | 17,369 | $5K | |
| 86901 | <1% | 9,339 | $5K | |
| 90685 | <1% | 663 | $5K | |
| 85055 | <1% | 1,867 | $5K | |
| 93925 | <1% | 122 | $5K | |
| 99221 | <1% | 123 | $5K | |
| 78227 | <1% | 26 | $5K | |
| 73120 | <1% | 380 | $5K | |
| 83690 | <1% | 31,945 | $5K | |
| 85018 | <1% | 2,432 | $5K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 52 | $5K |
| 36589 | <1% | 12 | $5K | |
| 74019 | <1% | 833 | $5K | |
| 95910 | <1% | 68 | $5K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 26 | $5K |
| 81003 | <1% | 10,363 | $4K | |
| 73620 | <1% | 532 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,844 | $4K |
| 99310 | Prolong nursin fac eval 15m | <1% | 342 | $4K |
| 80061 | Lipid panel | <1% | 1,376 | $4K |
| 76942 | <1% | 67 | $4K | |
| 57454 | <1% | 12 | $4K | |
| 85610 | <1% | 30,653 | $4K | |
| 90619 | <1% | 231 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,689 | $4K |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 189 | $4K |
| 0001A | <1% | 109 | $4K | |
| 99442 | <1% | 136 | $4K | |
| 76999 | <1% | 49 | $4K | |
| 0002A | <1% | 109 | $4K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,580 | $4K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 1,091 | $4K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 50 | $3K |
| 90696 | <1% | 244 | $3K | |
| 93458 | <1% | 13 | $3K | |
| 90688 | <1% | 328 | $3K | |
| 62270 | <1% | 13 | $3K | |
| 74022 | <1% | 1,585 | $3K | |
| 90656 | <1% | 933 | $3K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 129 | $3K |
| 99177 | <1% | 1,073 | $3K | |
| 90734 | <1% | 266 | $3K | |
| 73564 | <1% | 278 | $3K | |
| 0054A | <1% | 124 | $3K | |
| 93990 | <1% | 81 | $3K | |
| 80179 | <1% | 1,854 | $3K | |
| 71101 | <1% | 1,077 | $3K | |
| 72170 | <1% | 816 | $3K | |
| 84702 | <1% | 7,090 | $3K | |
| 64400 | <1% | 14 | $3K | |
| 96402 | <1% | 416 | $3K | |
| 99173 | <1% | 1,838 | $3K | |
| J9070 | Cyclophosphamide, 100 mg | <1% | 43 | $3K |
| 90700 | <1% | 250 | $3K | |
| 73090 | <1% | 1,449 | $3K | |
| 76886 | <1% | 26 | $3K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 4,435 | $3K |
| 64721 | <1% | 13 | $3K | |
| 70360 | <1% | 324 | $3K | |
| 82962 | <1% | 10,547 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 24,264 | $3K |
| 0004A | <1% | 130 | $3K | |
| 72082 | <1% | 70 | $3K | |
| 93246 | <1% | 74 | $3K | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 274 | $3K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 292 | $3K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 12 | $2K |
| 99218 | <1% | 44 | $2K | |
| 73660 | <1% | 595 | $2K | |
| 92250 | <1% | 68 | $2K | |
| 95800 | <1% | 26 | $2K | |
| 84100 | <1% | 4,888 | $2K | |
| 82565 | <1% | 1,961 | $2K | |
| 73521 | <1% | 167 | $2K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 26 | $2K |
| 73700 | <1% | 27 | $2K | |
| 82550 | <1% | 8,479 | $2K | |
| 90461 | <1% | 196 | $2K | |
| 51702 | <1% | 213 | $2K | |
| 99495 | <1% | 125 | $2K | |
| 82077 | <1% | 3,574 | $2K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 833 | $2K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,934 | $2K |
| 93018 | <1% | 348 | $2K | |
| 73100 | <1% | 154 | $2K | |
| 85730 | <1% | 10,749 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 35,268 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 29,635 | $2K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,252 | $2K |
| 93299 | <1% | 245 | $2K | |
| 85014 | <1% | 2,056 | $2K | |
| 90837 | Psychotherapy session, about an hour | <1% | 21 | $2K |
| 96161 | <1% | 884 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,839 | $2K |
| 72157 | <1% | 14 | $1K | |
| 90672 | <1% | 98 | $1K | |
| 93242 | <1% | 37 | $1K | |
| 99493 | <1% | 16 | $1K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 15 | $1K |
| 95885 | <1% | 38 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 36,022 | $1K |
| 99292 | <1% | 31 | $1K | |
| 90474 | <1% | 112 | $1K | |
| 73552 | <1% | 169 | $1K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 12 | $1K |
| 96523 | <1% | 21 | $1K | |
| 85652 | <1% | 4,570 | $1K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 25 | $1K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,975 | $1K |
| 20526 | <1% | 36 | $1K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 3,058 | $1K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 982 | $1K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 6,017 | $1K |
| 58571 | <1% | 13 | $1K | |
| 59514 | <1% | 14 | $1K | |
| 88304 | <1% | 2,337 | $1K | |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 25 | $1K |
| 74240 | <1% | 12 | $1K | |
| 92555 | <1% | 13 | $1K | |
| 86923 | <1% | 249 | $1K | |
| 0051A | <1% | 30 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 22,740 | $998.51 |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 197 | $985.99 |
| 84439 | <1% | 2,408 | $981.39 | |
| 93295 | <1% | 100 | $977.62 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 13,555 | $969.54 |
| 87186 | <1% | 5,430 | $955.46 | |
| 90480 | <1% | 27 | $947.20 | |
| 85007 | <1% | 241 | $939.17 | |
| 0111A | <1% | 24 | $916.83 | |
| 99241 | <1% | 32 | $900.05 | |
| 87070 | <1% | 3,790 | $878.63 | |
| 0052A | <1% | 32 | $876.80 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 107 | $846.19 |
| 88300 | <1% | 50 | $826.96 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 24,112 | $826.79 |
| 99382 | <1% | 12 | $825.08 | |
| 81002 | <1% | 4,042 | $782.65 | |
| 93923 | <1% | 26 | $782.47 | |
| 96411 | <1% | 1,302 | $773.91 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 10,450 | $761.29 |
| 77263 | <1% | 14 | $740.63 | |
| 82248 | <1% | 321 | $732.30 | |
| 99306 | Prolong nursin fac eval 15m | <1% | 29 | $724.34 |
| 77300 | <1% | 16 | $721.52 | |
| 93225 | <1% | 27 | $715.31 | |
| Q4010 | Cast supplies, short arm cast, adult (11 years +), fiberglass | <1% | 38 | $704.48 |
| 99305 | <1% | 74 | $697.18 | |
| 29065 | <1% | 13 | $690.45 | |
| 97163 | <1% | 15 | $683.98 | |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | <1% | 90 | $678.82 |
| 77334 | <1% | 19 | $678.12 | |
| 83615 | <1% | 909 | $648.93 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 14,002 | $623.44 |
| 99354 | <1% | 12 | $612.75 | |
| 87205 | <1% | 2,672 | $610.44 | |
| 87077 | <1% | 4,180 | $608.83 | |
| 20611 | <1% | 13 | $598.87 | |
| 73070 | <1% | 173 | $595.83 | |
| 73000 | <1% | 63 | $585.85 | |
| J2704 | Injection, propofol, 10 mg | <1% | 11,432 | $564.78 |
| 94010 | <1% | 15 | $533.41 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 12,289 | $520.88 |
| 87210 | <1% | 2,401 | $520.75 | |
| 30901 | <1% | 33 | $509.88 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 770 | $507.94 |
| 88342 | <1% | 915 | $502.76 | |
| 90687 | <1% | 65 | $499.86 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,864 | $485.77 |
| 96417 | <1% | 3,124 | $483.62 | |
| 87088 | <1% | 2,491 | $476.38 | |
| 76828 | <1% | 30 | $466.81 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,135 | $464.44 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 6,895 | $425.46 |
| 82570 | <1% | 513 | $420.53 | |
| 86920 | <1% | 490 | $402.14 | |
| 99217 | <1% | 12 | $393.45 | |
| V5275 | Ear impression, each | <1% | 15 | $393.13 |
| 96409 | <1% | 41 | $380.76 | |
| 90732 | <1% | 171 | $379.83 | |
| 93321 | <1% | 30 | $377.48 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 11,661 | $373.20 |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care | <1% | 14 | $346.61 |
| 73565 | <1% | 15 | $318.14 | |
| 74220 | <1% | 12 | $305.80 | |
| 82150 | <1% | 790 | $302.52 | |
| 82803 | <1% | 1,534 | $302.37 | |
| 96380 | <1% | 31 | $297.57 | |
| 93288 | <1% | 70 | $292.07 | |
| 72220 | <1% | 48 | $287.73 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,124 | $277.93 |
| 69209 | <1% | 73 | $271.00 | |
| 99451 | <1% | 12 | $257.52 | |
| 82009 | <1% | 1,282 | $252.80 | |
| 64494 | <1% | 29 | $247.27 | |
| 96401 | <1% | 79 | $246.79 | |
| 93280 | <1% | 57 | $245.43 | |
| 73600 | <1% | 33 | $244.37 | |
| 82728 | <1% | 87 | $243.59 | |
| 73060 | <1% | 117 | $242.09 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 2,888 | $242.07 |
| 80305 | <1% | 1,172 | $240.57 | |
| 84132 | <1% | 586 | $232.66 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,682 | $216.42 |
| 92504 | <1% | 48 | $208.21 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,554 | $200.45 |
| 84156 | <1% | 380 | $200.22 | |
| 84550 | <1% | 391 | $197.12 | |
| 93289 | <1% | 54 | $189.99 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 5,426 | $181.59 |
| 36591 | <1% | 109 | $178.92 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 8,302 | $178.08 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 2,913 | $176.78 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,196 | $176.18 |
| 97022 | <1% | 27 | $167.52 | |
| 76000 | <1% | 30 | $148.46 | |
| 99401 | <1% | 47 | $147.03 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,920 | $144.12 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 4,253 | $140.06 |
| 97016 | <1% | 26 | $137.99 | |
| 87075 | <1% | 1,129 | $124.28 | |
| 77001 | <1% | 13 | $112.45 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 1,561 | $111.80 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 4,930 | $111.65 |
| 80069 | <1% | 67 | $109.67 | |
| 92582 | <1% | 12 | $106.96 | |
| 88312 | <1% | 46 | $93.83 | |
| 17003 | <1% | 13 | $90.31 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 6,322 | $88.30 |
| G0009 | Administration of pneumococcal vaccine | <1% | 375 | $86.05 |
| 87045 | <1% | 198 | $85.92 | |
| 87324 | <1% | 125 | $83.77 | |
| 99406 | <1% | 448 | $82.37 | |
| 93297 | <1% | 24 | $82.35 | |
| 84450 | <1% | 60 | $80.44 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 30,316 | $79.80 |
| J1815 | Injection, insulin, per 5 units | <1% | 4,364 | $79.46 |
| 84520 | <1% | 78 | $76.17 | |
| 80076 | <1% | 41 | $74.83 | |
| 84460 | <1% | 77 | $71.90 | |
| 82140 | <1% | 181 | $70.46 | |
| 86308 | <1% | 805 | $69.67 | |
| 0240U | <1% | 1,495 | $66.00 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 966 | $62.22 |
| 83540 | <1% | 68 | $62.04 | |
| 87807 | <1% | 385 | $56.15 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 507 | $55.20 |
| 83550 | <1% | 51 | $54.48 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 5,623 | $53.30 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 3,539 | $52.40 |
| 94760 | <1% | 164 | $50.70 | |
| 36416 | <1% | 5,619 | $48.00 | |
| 87899 | <1% | 206 | $46.04 | |
| 36600 | <1% | 52 | $44.80 | |
| 96160 | <1% | 13 | $43.26 | |
| 87046 | <1% | 198 | $43.01 | |
| 87449 | <1% | 126 | $41.97 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 657 | $40.66 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,086 | $39.30 |
| 73650 | <1% | 15 | $38.90 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,258 | $38.52 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 334 | $38.52 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 896 | $38.52 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 2,187 | $38.52 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 2,066 | $38.52 |
| 82330 | <1% | 55 | $37.40 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 4,312 | $36.58 |
| 93294 | <1% | 12 | $36.21 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,027 | $35.48 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 552 | $34.20 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 7,900 | $32.50 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 8,596 | $29.16 |
| G0008 | Administration of influenza virus vaccine | <1% | 1,443 | $28.03 |
| 81000 | <1% | 277 | $25.75 | |
| 82947 | <1% | 77 | $20.86 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,202 | $20.69 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 1,666 | $16.93 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,592 | $16.65 |
| 80143 | <1% | 729 | $14.91 | |
| 83037 | <1% | 374 | $14.73 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 4,302 | $13.56 |
| 85046 | <1% | 13 | $10.83 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 978 | $8.98 |
| 84295 | <1% | 49 | $7.24 | |
| 82010 | <1% | 221 | $5.40 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 155 | $5.10 |
| 85384 | <1% | 17 | $5.02 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 2,233 | $2.18 |
| 99072 | <1% | 3,584 | $0.98 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 85 | $0.07 |
| 3078F | 0% | 14,002 | $0.00 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 41 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 14 | $0.00 |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 41 | $0.00 |
| 90662 | 0% | 248 | $0.00 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 0% | 1,683 | $0.00 |
| J0640 | Injection, leucovorin calcium, per 50 mg | 0% | 915 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 162 | $0.00 |
| 91311 | 0% | 49 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 163 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 3,165 | $0.00 |
| 91300 | 0% | 255 | $0.00 | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 257 | $0.00 |
| C1729 | Catheter, drainage | 0% | 419 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 155 | $0.00 |
| 3077F | 0% | 127 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 553 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 385 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 266 | $0.00 |
| 0353U | 0% | 372 | $0.00 | |
| A6021 | Collagen dressing, sterile, size 16 sq. in. or less, each | 0% | 1,288 | $0.00 |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 0% | 26 | $0.00 |
| C1788 | Port, indwelling (implantable) | 0% | 40 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 421 | $0.00 |
| 82272 | 0% | 26 | $0.00 | |
| 4004F | 0% | 13 | $0.00 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 395 | $0.00 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0% | 95 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 55 | $0.00 |
| 88112 | 0% | 17 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 214 | $0.00 |
| J9000 | Injection, doxorubicin hydrochloride, 10 mg | 0% | 21 | $0.00 |
| 89051 | 0% | 25 | $0.00 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 26 | $0.00 |
| Q4133 | Grafix prime, grafixpl prime, stravix and stravixpl, per square centimeter (add-on, list separately in addition to primary procedure) | 0% | 44 | $0.00 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | 0% | 29 | $0.00 |
| 90653 | 0% | 54 | $0.00 | |
| S0028 | Injection, famotidine, 20 mg | 0% | 130 | $0.00 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 14 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 12 | $0.00 |
| 77012 | 0% | 13 | $0.00 | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | 0% | 23 | $0.00 |
| 3074F | 0% | 15,863 | $0.00 | |
| J1836 | Injection, metronidazole, 10 mg | 0% | 215 | $0.00 |
| 3079F | 0% | 492 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 24,566 | $0.00 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 1,170 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 1,209 | $0.00 |
| H0049 | Alcohol and/or drug screening | 0% | 260 | $0.00 |
| C1769 | Guide wire | 0% | 4,040 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 376 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 390 | $0.00 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 32 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 694 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 158 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 270 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 164 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 897 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 589 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 554 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 110 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 341 | $0.00 |
| J9045 | Injection, carboplatin, 50 mg | 0% | 502 | $0.00 |
| 96368 | 0% | 548 | $0.00 | |
| J9267 | Injection, paclitaxel, 1 mg | 0% | 348 | $0.00 |
| 91307 | 0% | 461 | $0.00 | |
| 0352U | 0% | 12 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 632 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 78 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 54 | $0.00 |
| 3075F | 0% | 77 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 93 | $0.00 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | 0% | 16 | $0.00 |
| 97130 | 0% | 102 | $0.00 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 20 | $0.00 |
| 87081 | 0% | 29 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 24 | $0.00 |
| 91305 | 0% | 137 | $0.00 | |
| 90694 | 0% | 32 | $0.00 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 26 | $0.00 |
| 81015 | 0% | 22 | $0.00 | |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 0% | 14 | $0.00 |
| Q4131 | Epifix or epicord, per square centimeter | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECREATRY FOR ENROLLMENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.